



**University of
Zurich** ^{UZH}

**Zurich Open Repository and
Archive**

University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2017

**Diagnostic accuracy of coronary opacification derived from coronary
computed tomography angiography to detect ischemia: first validation
versus single-photon emission computed tomography**

Benz, Dominik C; Mikulicic, Fran; Gräni, Christoph; Grossmann, Marvin; Giannopoulos, Andreas A;
Messerli, Michael; Gebhard, Catherine; Gaemperli, Oliver; Buechel, Ronny R; Kaufmann, Philipp A;
Pazhenkottil, Aju P

DOI: <https://doi.org/10.1186/s13550-017-0342-8>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-142663>

Published Version



Originally published at:

Benz, Dominik C; Mikulicic, Fran; Gräni, Christoph; Grossmann, Marvin; Giannopoulos, Andreas A;
Messerli, Michael; Gebhard, Catherine; Gaemperli, Oliver; Buechel, Ronny R; Kaufmann, Philipp A;
Pazhenkottil, Aju P (2017). Diagnostic accuracy of coronary opacification derived from coronary com-
puted tomography angiography to detect ischemia: first validation versus single-photon emission com-
puted tomography. *EJNMMI Research*, 7(1):92.

DOI: <https://doi.org/10.1186/s13550-017-0342-8>

Anagnostopoulos - JCM submission

1 **Perioperative antibiotic prophylaxis has no effect on time to positivity and**
2 **proportion of positive samples: a cohort study of 64 *Cutibacterium acnes* bone**
3 **and joint infections.**

4

5 **Authors:** Alexia Anagnostopoulos^a, Daniel A. Bossard^a, Bruno Ledergerber^a, Patrick O.
6 Zingg^b, Annelies S. Zinkernagel^a, Christian Gerber^b, Yvonne Achermann^a

7

8 ^aDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich,
9 University of Zurich, Zurich, Switzerland

10 ^bDepartment of Orthopedics, University Hospital Balgrist, University of Zurich, Zurich,
11 Switzerland

12

13 **Keywords:** *Cutibacterium acnes*, perioperative antibiotic prophylaxis, osteomyelitis,
14 joint infection, biofilm, intraoperative diagnostic

15

16 **Running title:** Antibiotic prophylaxis in bone and joint infections

17

18 **Corresponding address:**

19 Yvonne Achermann, MD

20 Division of Infectious Diseases and Hospital Epidemiology

21 University Hospital Zurich, University of Zurich

22 Raemistrasse 100

23 CH-8091 Zurich

Anagnostopoulos - JCM submission

24 Switzerland

25 Phone: + 41 44 255 21 73; Fax: + 41 44 255 44 99

26 Email: yvonne.achermann@usz.ch

27

28 **Alternative corresponding address:**

29 Alexia Anagnostopoulos

30 Division of Infectious Diseases and Hospital Epidemiology

31 University Hospital Zurich, University of Zurich

32 Raemistrasse 100

33 CH-8091 Zurich

34 Switzerland

35 Phone: + 41 44 255 99 07; Fax: + 41 44 255 44 99

36 Email: alexia.anagnostopoulos@usz.ch

Anagnostopoulos - JCM submission

37 **ABSTRACT**

38 If a bone or joint infection is suspected, perioperative antibiotic prophylaxis is frequently
39 withheld until the intraoperative microbiological sampling has been performed. This
40 practice builds upon the hypothesis that perioperative antibiotics could render culture
41 results negative and thus impede tailored antibiotic treatment of infections. We aimed to
42 assess the influence of antibiotic prophylaxis within 30 to 60 minutes before surgery on
43 time to positivity of microbiological samples and proportion of positive samples in
44 *Cutibacterium acnes* bone and joint infections. Patients with at least one positive *C.*
45 *acnes* sample between January 2005 and December 2015 were included and classified
46 as 'infection' if at least 2 samples were positive, otherwise they were considered a
47 'contamination'. Kaplan-Meier curves were used to illustrate time to culture positivity.
48 We found 64 cases with a *C. acnes* infection and 46 classified as a *C. acnes*
49 contamination. Application of perioperative prophylaxis significantly differed between the
50 'infection' and 'contamination' group (72.8% versus 55.8%, $p < 0.001$). Within the
51 'infection' group, we found no difference in time to positivity between those who had or
52 had not received a perioperative prophylaxis (7.07 days (95% CI 6.4-7.7) vs. 7.11 days
53 (95% CI 6.8-7.5), $p = 0.3$). Also, there was no association between the proportion of
54 sample positivity and the application of perioperative prophylaxis (71.6% versus 65.9%,
55 $p = 0.39$). Since perioperative prophylaxis did not negatively influence the microbiological
56 yield in *C. acnes* infections, routine antibiotic prophylaxis can be routinely given to avoid
57 surgical site infections.

58

59

60 INTRODUCTION

61 In orthopedic surgery, antimicrobial prophylaxis is routinely given to reduce the risk for
62 surgical site infections and colonization of implanted orthopedic devices (1, 2). It is
63 recommended to give an antibiotic agent with bactericidal effect within a window of 30
64 to 60 minutes prior to skin incision in order to target skin commensal bacteria, such as
65 staphylococci, streptococci, or cutibacteria (2). Despite correctly applied antibiotic
66 prophylaxis, orthopedic bone and joint infections still occur in about 1-10% of cases (3).
67 These orthopedic bone and joint infections are typically caused by microorganisms
68 growing in biofilms. Usually, these biofilms are heterogeneously distributed, which is
69 challenging for an accurate localization of infection for diagnostic sampling (4). Biofilm
70 microorganisms are in a metabolically inactive, non-replicating state which make them
71 tolerant to our immune system and to antibiotics (5). Furthermore, biofilm bacteria are
72 enclosed in a polymeric matrix, which protects them from antimicrobial agents and
73 immune responses; biofilm bacteria are therefore difficult to reach, extract and cultivate
74 (4, 6). All of these factors contribute to the challenge of diagnosing biofilm infections
75 including bones and joint infections. Due to these difficulties, when a bone or joint
76 infection is suspected, and surgical treatment is necessary, application of perioperative
77 antibiotic prophylaxis is oftentimes withheld with the goal of increasing the
78 microbiological yield of positive intraoperative biopsy cultures to identify the pathogen
79 (7-10). Only knowing the causative microorganism of the infection allows a correct
80 tailored longterm antimicrobial treatment

81 However, recent studies (11-15) have shown that exposure to antibiotic agents
82 as perioperative single-shot prophylaxis ahead of the intraoperative microbiological

Anagnostopoulos - JCM submission

83 sampling is not associated with an increase in culture-negative results. Furthermore,
84 studies claim that perioperative antibiotic prophylaxis is needed in septic orthopedic
85 surgeries since it significantly reduces infection rates (16-18). However, these studies
86 were of small sample size, and the heterogeneity of the infections including both virulent
87 and low-virulent pathogens are major concerns.

88 *C. acnes* is a slow growing pathogen, which is often involved in bone and joint
89 infections (19) and is therefore qualified for studying the effect of preoperative antibiotic
90 prophylaxis in orthopedic settings. Since previous studies primarily assessed the
91 influence of preoperative prophylaxis on intraoperative culture results, studies
92 examining the number of positive samples and the time to positivity or confirmation of
93 the infection are lacking.

94 This study builds upon prior results from a large and homogenous cohort of
95 patients with suspected *C. acnes* bone and joint infections (6). We aimed to assess the
96 effect of preoperative antibiotic prophylaxis on time to positivity of *C. acnes* samples,
97 which is a crucial factor for the physician with regard to further therapeutic
98 management. Furthermore, we evaluated the number of positive samples and the time
99 to confirmation of a *C. acnes* infection in patients with and without perioperative
100 antibiotic prophylaxis.

101

102 **METHODS**

103 **Study population**

104 We retrospectively included patients from the University Hospital Balgrist in Zurich with
105 at least one positive intraoperative sample for *C. acnes*, isolated between January 2005

Anagnostopoulos - JCM submission

106 and December 2015. We excluded patients with no available data on antibiotic
107 prophylaxis at the time of surgery. Since antibiotic treatment might influence the time to
108 positivity of *C. acnes* growth, we also excluded samples from patients who had taken
109 antibiotics for ≥ 24 h within 14 days prior to sample acquisition. The University Hospital
110 Balgrist in Zurich, Switzerland, is an orthopedic clinic specialized in bone and joint
111 infections. Approximately 5000 surgical procedures are annually performed.

112 For clinical and demographic parameters at the time of diagnostic work-up, the patient
113 clinical database of the orthopedic clinic and the prospective database of the infectious
114 diseases consultation service were accessed. Microbiological data were collected using
115 the database of the Institute of medical microbiology, University of Zurich, Zurich,
116 Switzerland.

117 Within the same patient, same hospitalization period, same surgery and same
118 infection site, all samples were clustered as one diagnostic set per patient case,
119 regardless if the sample came back positive or negative. Patients were grouped into the
120 following two groups: 'infection' group if *C. acnes* was detected in at least two different
121 samples within the same patient case and 'contamination' group if there was only one
122 positive sample with *C. acnes*. In order to ensure an accurate allocation to one of the
123 two groups, only cases with three or more analyzable samples were included in this
124 analysis (10, 20).

125 The study was approved by the institutional review board in Zurich, Switzerland
126 (KEK Zurich number 2016-00145).

127

128 **Analysis and statistical methods**

Anagnostopoulos - JCM submission

129 For each sample of a patient diagnostic set, we collected details about the diagnostic
130 method used for detection of *C. acnes*, such as tissue or bone samples, sonication fluid,
131 synovial fluid or wound swab, and Gram staining.

132 We calculated time to positivity of *C. acnes* growth for each positive sample as
133 difference in days between start of microbiological culture and identification of *C. acnes*.
134 Among the 'infection' group, time to positivity was referring to culture positivity of the
135 second positive sample to confirm the infection and account for possible contamination.

136 We analyzed the proportion of positive microbiological samples (ratio of positive
137 samples to the total of all samples taken for each patient) in order to account for the
138 larger number of samples taken if an infection was suspected during surgery. We
139 performed a sensitivity analysis to assess potential associations and systematic
140 distortion of the results by the larger number of samples per patient required to be
141 classified into the 'infection' group. We therefore conducted a Cox proportional hazards
142 regression with robust standard errors, adjusted for the number of samples taken and
143 allowing for clustering of samples within patients.

144 Statistical analysis was performed using Stata 15.0 SE (StataCorp, College
145 Station, TX). We used parametric (Student's t-test) and non-parametric tests (Wilcoxon
146 rank-sum test for continuous variables, Fisher's exact test for categorical variables) to
147 compare variables both on a patient or on a sample level, whichever seemed
148 appropriate.

149 We used Kaplan-Meier curves to illustrate the number of days from the
150 intraoperative sampling to culture positivity both the 'infection' and 'contamination'

Anagnostopoulos - JCM submission

151 group. Differences between the times to positivity of both groups were analyzed by
152 using log-rank tests.

153

154 Microbiological processing*155 Diagnostic cultures*

156 All the applied preanalytic and cultivation processes, including the incubation times of
157 10 days, have been previously described in detail (6). Tissue samples were vortexed,
158 homogenized, and incubated on agar plates and thioglycolate broth, yet, bone samples
159 were inoculated in thioglycolate broth only. Explanted hardware was sonicated, and
160 cultivated on agar based media and thioglycolate, as recently published (6). For the
161 sonication samples, a threshold of 50 colony-forming units (CFU)/ml bacteria on agar
162 plates was considered positive.

163

164 Time to positivity of C. acnes growth

165 As previously described (6), time to positivity was defined as the time (in days) between
166 the start of microbiological culture and one of the following: 1) *C. acnes* - typical
167 colonies on agar plates, 2) turbidity in thioglycolate broth, or 3) a positive signal in blood
168 culture bottles for which *C. acnes* was subsequently identified on agar plates.

169

170 RESULTS**171 Clinical data and perioperative antibiotic prophylaxis**

172 *Patient level*

Anagnostopoulos - JCM submission

173 A total of 110 patients, predominantly male (69.1%) and with a median age of 58.5
174 years (interquartile range (IQR) 50-68) contributed to overall 550 intraoperative
175 samples, collected between January 2005 and December 2015. Among the most
176 common sample sites were shoulder (N = 72) and hip (N = 25), followed by knee (N =
177 6). In 87.3% patients, a prosthesis (58/110) or another foreign body (38/110) was
178 present. In 64 patients (58.2%), an infection with *C. acnes* was diagnosed, defined as at
179 least two positive samples, while identification of *C. acnes* in only one sample of the
180 remaining 46 patients (41.8%) did not fulfill the criteria of a proven infection and was
181 therefore considered contamination.

182 We analyzed 550 samples, of these 484 (88%) were tissue biopsies (including
183 wound swabs and fluids), 54 (9.8%) sonication fluid from removed implants, and 12
184 (2.2%) bone biopsies. This distribution did not significantly differ between the 'infection'
185 group and the 'contamination' group ($p=0.49$). The mean number of samples taken per
186 patient were 5.3 in the 'infection' group (IQR 4-8) and 4.5 in the 'contamination' group
187 (IQR 3-6). In the 'infection' group, a median of three samples (IQR 2-5) were positive
188 with *C. acnes*. Patient characteristics and sample specifications are shown in Table 1.

189 Out of the 64 patients in the 'infection' group, 44 (68.8%) had not received
190 perioperative prophylaxis until intraoperative biopsies for microbiology had been taken,
191 compared to only 23 (50%) in the 'contamination' group ($p=0.047$). If antibiotic
192 prophylaxis had been applied, it was mostly cefuroxime (83.7%), followed by cefazolin
193 (9.3%) (Table 1). Distribution of infection and antibiotic prophylaxis status on a patient
194 and sample level are illustrated in Fig. 1.

195

196 Time to sample positivity

197 A total of 274 out of 550 (49.8%) analyzed samples detected *C. acnes*. Among those,
198 the mean time to culture positivity as defined for each group was significantly shorter in
199 the 228 samples of the 'infection' group (6.04 days, 95% CI 5.71-6.37) as compared to
200 the 46 samples of the 'contamination' group (8.37 days, 95% CI 7.69-9.05, $p < 0.001$)
201 (Fig. 2a).

202 In order to investigate the influence of perioperative prophylaxis on cultivation
203 time of *C. acnes* within a comparable group of patients, we assessed the time to sample
204 positivity in the 'infection' group only. Of all 342 samples of the 64 patients in the
205 'infection' group, 72.8% (249/342) were collected in patients who had not been exposed
206 to perioperative prophylaxis as compared to the low percentage of 27.2% (93/342) with
207 prophylaxis exposure (Fig. 1). However, the time to positivity within the 'infection' group
208 did not significantly differ between those samples collected from patients exposed to
209 perioperative prophylaxis (mean 7.07, 95% CI 6.4-7.7) and those not exposed to
210 perioperative prophylaxis (mean 7.11, 95% CI 6.8-7.5) ($p = 0.3$) (Fig. 2b). The sensitivity
211 analysis confirmed that this finding was not affected by the total number of samples
212 taken per patient (adjusted Hazard Ratio 0.84 (0.60-1.18), $p = 0.31$).

213

214 Proportion of sample positivity

215 Perioperative antibiotic prophylaxis could also have an influence on the number of
216 positive samples within a case. Overall, the proportion of sample positivity among all
217 110 patients ('infection' and 'contamination' group combined) was 50.9% (95% CI 45.4-
218 56.5). In the 67/110 patients (60.9%), in which no perioperative prophylaxis had been

Anagnostopoulos - JCM submission

219 applied, the proportion of sample positivity was 54.5% (95% CI 46.8-62.1), while the
220 remaining 43 patients (39.1%) with perioperative prophylaxis had a proportion of sample
221 positivity of 45.5%. There was no significant difference in the proportion of sample
222 positivity between the patients with and without perioperative prophylaxis ($p=0.12$).

223 Among the 64 patients with a proven *C. acnes* infection, the proportion of sample
224 positivity was 69.8% (95% CI 63.8-75.8). Of these 64 patients, 44 (68.8%) had not
225 received perioperative prophylaxis; their proportion of sample positivity was 71.6% (95%
226 CI 64.1-79.1). The remaining 20 patients (31.2%) with perioperative prophylaxis had a
227 proportion of sample positivity of 65.9% (95% CI 55.3-76.5). Hence, in the 'infection'
228 group only, there was no significant difference in the proportion of sample positivity
229 between infection patients with perioperative prophylaxis and those without application
230 of antibiotics before or during surgery ($p=0.39$).

231

232 DISCUSSION

233 This is the first study analyzing the influence of perioperative prophylaxis on time to
234 diagnosis and proportion of positive samples in a homogenous group of bone and joint
235 infections caused by the same pathogen, *C. acnes*. As bone and joint infections are
236 causing significant morbidity for the individual and account for large health care
237 expenses (21), the combination of surgical interventions and targeted biofilm-active
238 antibiotic treatment against the causative pathogen is crucial in order to regain
239 functionality (8). Therefore, the timely microbiological identification is one of the
240 mainstays in treating orthopedic infections. We showed that administering perioperative
241 antibiotic prophylaxis did not affect the time to diagnosis of *C. acnes* infection and

Anagnostopoulos - JCM submission

242 therefore will not prolong the timely identification of pathogen in bone and joint
243 infections. Our findings support the routine administration of perioperative prophylaxis,
244 which has previously shown to significantly lower surgical site infection rates (1, 2, 22).
245 One systematic review (18) found a relative risk reduction of 81% of developing
246 postsurgical wound infections among patients with total hip and knee replacements, if
247 perioperative prophylaxis had been administered correctly. Since hip and knee were
248 also the most common surgical sites in our population, a risk reduction of wound
249 infections to this extent would have major implications on the morbidity of our patients
250 and thus our findings.

251

252 Proportion of positive samples within a diagnostic set in our study population of
253 *C. acnes* infections did not differ between patients with and without perioperative
254 prophylaxis (65.9% versus 68.8%). Bone and joint infections are typically biofilm-
255 associated infections, in which bacteria are protected from antibiotic agents (8). In order
256 to kill biofilm bacteria in the stationary phase, bactericidal antimicrobial substances (23)
257 with a good ability to penetrate the biofilm, such as rifampin are required (8).
258 Cephalosporins, commonly used for perioperative prophylaxis, do not have these
259 characteristics. Since the application of a preoperative single-shot antibiotic prophylaxis
260 is primarily active against planktonic bacteria in the bloodstream and tissue, but is
261 unable to penetrate the biofilm, antibiotic prophylaxis has no effect on culture positivity
262 of intraoperative microbiological samples (13, 15, 24).

263

Anagnostopoulos - JCM submission

264 We recommend the routine administration of antibiotic prophylaxis, even when an
265 *C. acnes* infection is suspected, as the administration of a single shot antibiotic
266 prophylaxis did not affect the intraoperative diagnostic yield. Our recommendation is in
267 line with the American Academy of Orthopedic Surgeons (AAOS) guidelines from 2011
268 (15) as well as with a recently published systematic review (24) assessing the influence
269 of perioperative prophylaxis on culture yield among patients with prosthetic joint
270 infections. The authors of both studies (15, 24) did not find a significant difference
271 between the prophylaxis and the non-prophylaxis group, which would outweigh the risk
272 of a postoperative infectious complication if perioperative prophylaxis was withheld. The
273 recommendation of our study, the AAOS guidelines (15), and the systematic review (24)
274 to routinely apply perioperative prophylaxis is not yet included in the French guidelines
275 for bone and joint infections (9) nor in the IDSA guidelines (10) from 2013, which
276 recommend to withhold antimicrobial prophylaxis when the preoperative risk of a
277 prosthetic joint infection is high based on the results of the history, exams,
278 sedimentation rate, CRP level, and preoperative aspiration.

279

280 The strength of our study is the large homogenous cohort of 64 cases with a
281 proven *C. acnes* bone or joint infection. This is to our knowledge, the largest cohort
282 study to date that is focusing exclusively on this low-virulent and yet very relevant
283 pathogen within the orthopedic context. For our study, we did explicitly not choose a
284 virulent pathogen, such as *Staphylococcus aureus*, since identification of virulent
285 pathogens is often less challenging, even if a short course of antibiotic treatment had
286 been given prior to surgery. A further strength of our study is the novel aspect of our

Anagnostopoulos - JCM submission

287 analysis, including the comparison of time to positivity between different patient groups
288 as well as analysis of the proportion of positive samples within the patient clusters. The
289 long-running microbiological protocols for all bone and joint samples in our cohort
290 secured the comparability of the culture results. A limitation of our study is the
291 retrospective study design, which set certain restrictions in terms of availability of
292 information and comparison to control groups.

293

294 In conclusion, based on to our results in patients with *C. acnes* bone and joint
295 infections, perioperative antibiotic prophylaxis did not influence the intraoperative
296 diagnostic yield of microbiological cultures. We therefore recommend that perioperative
297 antibiotic prophylaxis in elective orthopedic infection operations should be routinely
298 given and not be withheld until all intraoperative biopsies were taken . This will minimize
299 on the one hand the risk of bacterial infection of the surgical field and on the other hand
300 this will protect the newly implanted hardware.

301

302 Funding

303 Yvonne Achermann is supported by the academic career program "Filling the gap" of
304 the Medical Faculty of the University of Zurich.

305 **Financial disclosure:** None reported. No conflicts of interests.

306 Acknowledgment

307 We thank Mazda Farshad and Reinhard Zbinden for the critical reading of the paper
308 and the technicians of the Institute of Medical Microbiology of the University of Zurich for
309 their expert help and assistance.

310

Anagnostopoulos - JCM submission

15

311 REFERENCES

- 312 1. **Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK,**
313 **Fish DN, Napolitano LM, Sawyer RG, Slain D, Steinberg JP, Weinstein RA.**
314 2013. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg
315 Infect (Larchmt) **14**:73-156.
- 316 2. **Classen DC, Evans RS, Pestotnik SL, Horn SD, Menlove RL, Burke JP.**
317 1992. The timing of prophylactic administration of antibiotics and the risk of
318 surgical-wound infection. N Engl J Med **326**:281-286.
- 319 3. **Darouiche RO.** 2001. Device-associated infections: a macroproblem that starts
320 with microadherence. Clin Infect Dis **33**:1567-1572.
- 321 4. **Hoiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O.** 2010. Antibiotic
322 resistance of bacterial biofilms. Int J Antimicrob Agents **35**:322-332.
- 323 5. **Stewart PS.** 2015. Antimicrobial Tolerance in Biofilms. Microbiol Spectr **3**.
- 324 6. **Bossard DA, Ledergerber B, Zingg PO, Gerber C, Zinkernagel AS, Zbinden**
325 **R, Achermann Y.** 2016. Optimal Length of Cultivation Time for Isolation of
326 *Propionibacterium acnes* in Suspected Bone and Joint Infections Is More than 7
327 Days. J Clin Microbiol **54**:3043-3049.
- 328 7. **Al-Mayahi M, Cian A, Lipsky BA, Suva D, Muller C, Landelle C, Miozzari HH,**
329 **Uckay I.** 2015. Administration of antibiotic agents before intraoperative sampling
330 in orthopedic infections alters culture results. J Infect **71**:518-525.
- 331 8. **Zimmerli W, Trampuz A, Ochsner PE.** 2004. Prosthetic-joint infections. N Engl
332 J Med **351**:1645-1654.

Anagnostopoulos - JCM submission

- 333 9. **Anonymous.** 2010. Recommendations for bone and joint prosthetic device
334 infections in clinical practice (prosthesis, implants, osteosynthesis). Societe de
335 Pathologie Infectieuse de Langue Francaise. *Med Mal Infect* **40**:185-211.
- 336 10. **Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM,**
337 **Rao N, Hanssen A, Wilson WR, America IDSo.** 2013. Diagnosis and
338 management of prosthetic joint infection: clinical practice guidelines by the
339 Infectious Diseases Society of America. *Clin Infect Dis* **56**:e1-e25.
- 340 11. **Burnett RS, Aggarwal A, Givens SA, McClure JT, Morgan PM, Barrack RL.**
341 2010. Prophylactic antibiotics do not affect cultures in the treatment of an
342 infected TKA: a prospective trial. *Clin Orthop Relat Res* **468**:127-134.
- 343 12. **Ghanem E, Parvizi J, Clohisy J, Burnett S, Sharkey PF, Barrack R.** 2007.
344 Perioperative antibiotics should not be withheld in proven cases of periprosthetic
345 infection. *Clin Orthop Relat Res* **461**:44-47.
- 346 13. **Perez-Prieto D, Portillo ME, Puig-Verdie L, Alier A, Gamba C, Guirro P,**
347 **Martinez-Diaz S, Horcajada JP, Trampuz A, Monllau JC.** 2016. Preoperative
348 antibiotic prophylaxis in prosthetic joint infections: not a concern for intraoperative
349 cultures. *Diagn Microbiol Infect Dis* **86**:442-445.
- 350 14. **Tetreault MW, Wetters NG, Aggarwal V, Mont M, Parvizi J, Della Valle CJ.**
351 2014. The Chitranjan Ranawat Award: Should prophylactic antibiotics be
352 withheld before revision surgery to obtain appropriate cultures? *Clin Orthop Relat*
353 *Res* **472**:52-56.
- 354 15. **Della Valle C, Parvizi J, Bauer TW, DiCesare PE, Evans RP, Segreti J,**
355 **Spanghel M, Watters WC, 3rd, Keith M, Turkelson CM, Wies JL, Sluka P,**

Anagnostopoulos - JCM submission

- 356 **Hitchcock K.** 2011. American Academy of Orthopaedic Surgeons clinical
357 practice guideline on: the diagnosis of periprosthetic joint infections of the hip and
358 knee. *J Bone Joint Surg Am* **93**:1355-1357.
- 359 16. **Trampuz A, Zimmerli W.** 2006. Antimicrobial agents in orthopaedic surgery:
360 Prophylaxis and treatment. *Drugs* **66**:1089-1105.
- 361 17. **Oishi CS, Carrion WV, Hoaglund FT.** 1993. Use of parenteral prophylactic
362 antibiotics in clean orthopaedic surgery. A review of the literature. *Clin Orthop*
363 *Relat Res*:249-255.
- 364 18. **AlBuhairan B, Hind D, Hutchinson A.** 2008. Antibiotic prophylaxis for wound
365 infections in total joint arthroplasty: a systematic review. *J Bone Joint Surg Br*
366 **90**:915-919.
- 367 19. **Achermann Y, Tran B, Kang M, Harro JM, Shirtliff ME.** 2015.
368 Immunoproteomic Identification of In Vivo-Produced *Propionibacterium acnes*
369 Proteins in a Rabbit Biofilm Infection Model. *Clin Vaccine Immunol* **22**:467-476.
- 370 20. **Atkins BL, Athanasou N, Deeks JJ, Crook DW, Simpson H, Peto TE,**
371 **McLardy-Smith P, Berendt AR.** 1998. Prospective evaluation of criteria for
372 microbiological diagnosis of prosthetic-joint infection at revision arthroplasty. The
373 OSIRIS Collaborative Study Group. *J Clin Microbiol* **36**:2932-2939.
- 374 21. **Kurtz SM, Lau E, Watson H, Schmier JK, Parvizi J.** 2012. Economic burden of
375 periprosthetic joint infection in the United States. *J Arthroplasty* **27**:61-65.e61.
- 376 22. **Uçkay I, Harbarth S, Peter R, Lew D, Hoffmeyer P, Pittet D.** 2010. Preventing
377 surgical site infections. *Expert Review of Anti-infective Therapy* **8**:657-670.

- 378 23. **Baldoni D, Haschke M, Rajacic Z, Zimmerli W, Trampuz A.** 2009. Linezolid
379 alone or combined with rifampin against methicillin-resistant *Staphylococcus*
380 *aureus* in experimental foreign-body infection. Antimicrob Agents Chemother
381 **53**:1142-1148.
- 382 24. **Wouthuyzen-Bakker M, Benito N, Soriano A.** 2017. The effect of preoperative
383 antimicrobial prophylaxis on intraoperative culture results in patients with a
384 suspected or confirmed prosthetic joint infection. A systematic review. J Clin
385 Microbiol **55**:2765-2774.
- 386

Anagnostopoulos - JCM submission

387 **TABLES AND FIGURES**

388 **Table 1.** Clinical characteristics of 64 patients with bone and joint infections caused by
 389 *C. acnes* (≥ 2 positive *C. acnes* samples) and 46 cases with no infection (1 positive *C.*
 390 *acnes* sample).

| | Overall N=110 (%) | Infection N=64 (%) | No infection N=46 (%) | <i>p</i> value |
|---|----------------------|-----------------------|--------------------------|----------------|
| Patient characteristics | | | | |
| Male gender (%) | 76 (69.1) | 45 (70.3) | 31 (67.4) | 0.84 |
| Age [years], median (IQR) | 58.5 (50-68) | 58.5 (47.5-68) | 58.5 (51-69) | 0.48 |
| Sample site | | | | 0.06 |
| Shoulder | 72 (65.5) | 47 (73.4) | 25 (54.4) | |
| Hip | 25 (22.7) | 12 (18.8) | 13 (28.3) | |
| Spine | 5 (4.6) | 4 (6.2) | 1 (2.2) | |
| Knee | 6 (5.5) | 1 (1.6) | 5 (10.9) | |
| Other | 2 (1.7) | 0 (0.0) | 2 (4.2) | |
| Sample type | | | | 0.38 |
| Tissue and/or bone | 79 (71.8) | 48 (75.0%) | 31 (67.4%) | |
| Sonication fluid | 32 (28.2) | 16 (25.0%) | 15 (32.6%) | |
| Number samples, mean (IQR) | 5 (3-6) | 5.3 (4-8) | 4.5 (3-6) | <0.001 |
| Total positive samples per case, median (IQR) | 2 (1-4) | 3 (2-5) | 1 | |
| Presence of foreign body | | | | 0.28 |
| Prosthesis | 58 (52.7) | 31 (48.4) | 27 (58.7) | |
| Other foreign body | 38 (34.5) | 27 (42.2) | 11 (23.9) | |

Anagnostopoulos - JCM submission

| | Overall N=110 (%) | Infection N=64 (%) | No infection N=46 (%) | <i>p value</i> |
|----------------------------------|----------------------|-----------------------|--------------------------|----------------|
| Perioperative prophylaxis | | | | |
| Yes | 43 (39.1) | 20 (31.2%) | 23 (50.0%) | 0.05 |
| Prophylaxis agent | | | | 0.14 |
| Cefuroxime | 36 (32.7) | 17 (26.6) | 19 (41.3) | |
| Cefazolin | 4 (3.6) | 2 (3.1) | 2 (4.4) | |
| Clindamycin | 2 (1.8) | 0 (0.0) | 2 (4.4) | |
| Vancomycin | 1 (0.9) | 1 (1.6) | 0 (0.0) | |

391


392

Anagnostopoulos - JCM submission

393 **Fig. 1.** Distribution of infection and preoperative prophylaxis status on a patient and
394 sample level. 68.8% of the patients in the 'infection' group did not receive antibiotic
395 prophylaxis, compared to 50% of patients in the 'contamination' group.

396 Abbreviations: AB, antibiotic

397




398

399

Anagnostopoulos - JCM submission

400 **Fig. 2a.** Kaplan-Meier curve illustrating the proportion of sample positivity with *C. acnes*
 401 in all 274 positive samples, stratified by infection status (228 in the 'infection' group vs.
 402 46 in the 'contamination' group). The median time to positivity was 6 days for the
 403 'infection' group and 9 days for the 'contamination' group (log rank $p < 0.001$). The
 404 colored areas represent the 95% confidence interval.




405

406

407

Anagnostopoulos - JCM submission

408 **Fig. 2b.** Kaplan-Meier curve illustrating the proportion of sample positivity with *C. acnes*
 409 in the 342 samples of the 'infection' group, stratified by preoperative prophylaxis (93 in
 410 the 'prophylaxis' group vs. 249 in the 'no prophylaxis' group). The median time to
 411 positivity was 8 days for the 'prophylaxis' group and 7 days for the 'no prophylaxis'
 412 group (log rank $p=0.3$). The colored areas represent the 95% confidence interval.



413

414

Anagnostopoulos - JCM submission

415 **FIGURE LEGENDS**

416 **Fig. 1.** Distribution of infection and preoperative prophylaxis status on a patient and
417 sample level. 68.8% of the patients in the 'infection' group did not receive antibiotic
418 prophylaxis, compared to 50% of patients in the 'contamination' group.

419 Abbreviations: AB, antibiotic

420

421 **Fig. 2a.** Kaplan-Meier curve illustrating the proportion of sample positivity with *C. acnes*
422 in all 274 positive samples, stratified by infection status (228 in the 'infection' group vs.
423 46 in the 'contamination' group). The median time to positivity was 6 days for the
424 'infection' group and 9 days for the 'contamination' group (log rank $p < 0.001$). The
425 colored areas represent the 95% confidence interval.

426

427 **Fig. 2b.** Kaplan-Meier curve illustrating the proportion of sample positivity with *C. acnes*
428 in the 342 samples of the 'infection' group, stratified by preoperative prophylaxis (93 in
429 the 'prophylaxis' group vs. 249 in the 'no prophylaxis' group). The median time to
430 positivity was 8 days for the 'prophylaxis' group and 7 days for the 'no prophylaxis'
431 group (log rank $p = 0.3$). The colored areas represent the 95% confidence interval.

432

